Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD33CART in Children and Young Adults With Relapsed/Refractory AML
NCT03971799Phase 2Active, not recruiting
- Sponsor
- Center for International Blood and Marrow Transplant Research
- Start
- Jan 2020
- Primary completion
- Dec 2029
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label trial of CD33 CAR-T in acute myeloid leukemia (AML) (2 arms), sponsored by Center for International Blood and Marrow Transplant Research. Primary endpoints: Maximum Tolerated Dose and Morphologic Remission Rate. Started Jan 2020; status: active, not recruiting.
02
Drugs
CD33 CAR-T
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03971799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03971799.